In collaboration with
The purpose of this research is to analyze the entire dielectric substance of each patient and SARS-CoV-2 using samples of about 1,000 patients with COVID-19 in Daegu and
Theragen Bio plans to use this research for identifying the infectious correlation on the dielectric substances between patients and COVID-19 to apply it to the development of vaccines in the future.
Based on its own Next Generation Sequencing (NGS), the company uses the RNA analyzing system of COVID-19 to sequence about 30,000 whole RNA genomes per the virus. The virus is so unstable to cause frequent mutations. However, this research method will serve as a solution to check the variation, reproduction, and generation of the RNA.
In addition, the research will trace back the evolution of COVID-19 to identify the spreading cause between humans and predict clinical patterns, thereby selecting high-risk groups, improving the efficiency of PCR-based diagnosis, and securing evidence of the prevention strategies.
Meanwhile, the company has participated in the study of high-resolution genetic map for SARS-CoV-2, which was developed in collaboration with
This study found the location of the gene and its variation in RNA to determine the transcriptome compositions and proliferation principles of the virus. In May, it also found that the patients with COVID-19 related to the club in Itaewon,
The company successfully traced the infection path by sequencing the dielectric substances and RNA transcriptomes of the confirmed at the club.
Theragen Bio was separated from
Media Contact
Company
Contact Person:
Email: ngssales@theragenetex.com
Phone: +82-31-888-9313
Country:
Website: www.theragenbio.com
Source: www.abnewswire.com
.
(C) 2020 M2 COMMUNICATIONS, source